Wolfe says Elevance Health has most conservative Medicaid enrollment guidance

Wolfe Research’s Medicaid tracker shows continued enrollment attrition, with April data declining 37 bps and several states still trending below expectations. Elevance Health has the most conservative 2026 Medicaid guidance at negative 8%, while Wolfe estimates YTD enrollment declines of 1.0% to 1.9% across major managed-care names. Molina raised same-store attrition guidance to 6% from 2%, reinforcing cautious commentary across the Medicaid managed-care group.

Analysis

Managed Medicaid is becoming a relative game of who has the cleanest book and the least pricing leakage, not who has the biggest enrollment footprint. The key second-order effect is that slower-than-expected disenrollment keeps acuity mix worse for longer: lower-risk members leave first, so “benign” top-line retention can still pressure MLR and make 2026 bids conservatively set across the group. That matters most for names with the largest Medicaid concentration and the least ability to reprice quickly, with ELV and CNC the most exposed to earnings revisions if trend data keep undershooting guidance.

The near-term setup is less about absolute enrollment and more about how much of the attrition is already embedded in guidance versus still a surprise. Molina’s higher attrition outlook is notable because it signals management is now treating elevated churn as persistent rather than transitory, which can actually be positive for valuation if it reduces the odds of a second-downward revision later this year. By contrast, UNH and CVS have more diversification, so Medicaid weakness is a smaller P&L issue but still a signal that state funding and rate adequacy remain behind the curve.

The market is likely underappreciating the timing mismatch: enrollment can improve or stabilize within months, but rate resets and 2026 bid assumptions lag by multiple quarters. That creates a window where share prices can react more to data cadence than earnings, especially if state-by-state reports continue to show a low- to mid-single-digit decline profile. The main reversal catalyst would be a faster normalizing of redetermination effects or state-level funding actions that restore margin confidence before 2026 bids are locked.

Consensus may be too focused on “less bad” attrition rather than the margin implications of selection bias and delayed repricing. If the current run-rate persists, the most vulnerable names are those where guidance already embeds a recovery that enrollment data has yet to confirm. Conversely, if the market has already discounted worst-case Medicaid pressure, the downside from here is more likely in estimate revisions than in multiple compression.

Key Decisions for Investors

• Short ELV versus long UNH for 1-3 months: ELV has the weakest Medicaid setup and the highest risk of 2026 estimate cuts, while UNH offers better diversification and lower earnings sensitivity to state-level churn.
• Pair long MOH / short CNC on a 2-4 month horizon: MOH’s higher attrition disclosure may de-risk future surprises, while CNC still looks more exposed to persistent underfunding and guidance drift.